TrueBlue (TBI) Earnings Analysis
TrueBlue (TBI) next reports earnings on 2026-08-03, consensus EPS -0.1 USD. Last quarter (2026-02-18) it missed with EPS -0.25 USD vs -0.08 USD est (-212.5%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -4.67.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TBI next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -0.1 USD |
| Revenue estimate | 0.42B |
TBI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-18 | -0.25 USD | -0.08 USD | -212.5% | Miss |
| 2025-11-03 | 0.03 USD | -0.09 USD | +133.3% | Beat |
| 2025-08-04 | -0.07 USD | -0.31 USD | +77.4% | Beat |
| 2025-05-05 | -0.4 USD | -0.23 USD | -73.9% | Miss |
| 2025-02-19 | -0.02 USD | -0.16 USD | +87.5% | Beat |
| 2024-11-04 | -0.11 USD | -0.23 USD | +52.2% | Beat |
| 2024-08-05 | -0.35 USD | -0.0475 USD | -636.8% | Miss |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
TBI valuation and analyst view
| Trailing P/E | -4.67 |
|---|---|
| Trailing EPS | -1.77167 USD |
| Price / book | 0.98 |
| Dividend yield | 0.00% |
| Market cap | 0.25B |
| Analyst consensus | Buy (5 buy / 4 hold / 1 sell) |
| Avg price target | 5.75 USD |
Related research pages
Frequently asked questions
When is TrueBlue (TBI)'s next earnings date?
TrueBlue is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -0.1 USD and revenue estimate of 0.42B.
Did TBI beat earnings last quarter?
In its 2026-02-18 report, TBI posted EPS of -0.25 USD versus a -0.08 USD estimate — a miss of 212.5%.
What is TBI's earnings track record?
Over the last 7 reported quarters with consensus data, TBI beat estimates 4 times (57%).
What is TBI's current P/E ratio and EPS?
TBI trades at a trailing P/E of -4.67 on trailing EPS of -1.7716702604080279 USD.
What do analysts rate TBI?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 5.75 USD.